# Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

> **NCT07473167** · PHASE1,PHASE2 · RECRUITING · sponsor: **TICAROS Co., Ltd.** · enrollment: 98 (estimated)

## Conditions studied

- Relapsed Large B-cell Lymphoma
- Refractory Large B-cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- High-grade B-cell Lymphoma (HGBL)
- Transformed Follicular Lymphoma (TFL)
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)

## Interventions

- **DRUG:** TC011

## Key facts

- **NCT ID:** NCT07473167
- **Lead sponsor:** TICAROS Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-03
- **Primary completion:** 2028-02-11
- **Final completion:** 2028-03-10
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07473167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07473167, "Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07473167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*